Development of Xanamem, an isoform 1 specific inhibitor of 11‐βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach
Xanamem 是一种 11-βHSD 亚型 1 特异性抑制剂,其开发旨在作为一种促认知和疾病修饰疗法,用于治疗轻度/中度阿尔茨海默病。该研究采用药效学和生物标志物驱动的方法。
期刊:Journal of Family Medicine and Primary Care
影响因子:1
doi:10.4103/jfmpc.jfmpc_155_21
Mishra, Divyangi; Shukla, Ravindra; Rolan, Paul; Taylor, Jack; Seckl, Jonathan; Harrison, John E; Chen, Christopher Li‐Hsian; Farrell, Colm; Maruff, Paul; Woodward, Michael; Hilt, Dana